Anticoagulant therapy: basic principles, classic approaches and recent developments

被引:19
作者
Sinauridze, Elena I. [1 ,2 ]
Panteleev, Mikhail A. [1 ,2 ,3 ,4 ]
Ataullakhanov, Fazoil I. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Minist Hlth & Social Dev, Natl Res Ctr Hematol, Moscow 125167, Russia
[2] Russian Acad Sci, Ctr Theoret Problems Physicochem Pharmacol, Moscow, Russia
[3] Moscow MV Lomonosov State Univ, Dept Phys, Moscow, Russia
[4] HemaCore LLC, Moscow, Russia
[5] Fed Res & Clin Ctr Pediat Hematol Oncol & Immunol, Moscow, Russia
基金
俄罗斯基础研究基金会;
关键词
antithrombotic therapy; antiplatelet agents; blood coagulation; dabigatran; direct thrombin inhibitors; thrombosis; vitamin K antagonists; warfarin; heparin; MOLECULAR-WEIGHT HEPARIN; INTRAVENOUS UNFRACTIONATED HEPARIN; DIRECT THROMBIN INHIBITOR; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; FACTOR XA; DABIGATRAN ETEXILATE; INITIAL TREATMENT; UNSTABLE ANGINA;
D O I
10.1097/MBC.0b013e328355c9cb
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The standard multipotent anticoagulants (unfractionated and low molecular weight heparins, antagonists of vitamin K) are commonly used for treatment and/or prophylaxis of different thrombotic complications, such as deep vein thrombosis, thrombophilia, pulmonary embolism, myocardial infarction, stroke and so on. Advantages and shortcomings of these anticoagulants are considered. The modern tendencies to use small selective direct inhibitors of thrombin or factor Xa are surveyed. The search of the new targets in the coagulation cascade for development of new promising anticoagulants and improvement in antithrombotic therapy is discussed. Blood Coagul Fibrinolysis 23:482-493 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:482 / 493
页数:12
相关论文
共 98 条
[1]   Anticoagulation With Argatroban for Elective Percutaneous Coronary Intervention: Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationship of Coagulation Parameters [J].
Akimoto, Kei ;
Klinkhardt, Ute ;
Zeiher, Andreas ;
Niethammer, Margit ;
Harder, Sebastian .
JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (06) :805-818
[2]  
[Anonymous], NEW ANTICOAGULANTS C
[3]  
[Anonymous], 2006, REFL PROD MON, P44
[4]  
Ansell Jack, 2004, Curr Hematol Rep, V3, P357
[5]   Warfarin Versus New Agents: Interpreting the Data [J].
Ansell, Jack .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2010, :221-228
[6]   HIRUDIN IN ACUTE MYOCARDIAL-INFARCTION - SAFETY REPORT FROM THE THROMBOLYSIS AND THROMBIN INHIBITION IN MYOCARDIAL-INFARCTION (TIMI)-9A TRIAL [J].
ANTMAN, EM .
CIRCULATION, 1994, 90 (04) :1624-1630
[7]  
Argatroban Matsuo T., 2007, ARGATROBAN ANTITHROM, P1
[8]  
ATAULLAKHANOV FI, 2003, PROBLEMS HAEMATOL BL, V1, P7
[9]   Argatroban in the management of heparin-induced thrombocytopenia [J].
Babuin, Luciano ;
Pengo, Vittorio .
VASCULAR HEALTH AND RISK MANAGEMENT, 2010, 6 :813-819
[10]   Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa [J].
Bauer, K. A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 :12-19